Panel recommends Vioxx return to market in Canada

A medical advisory panel in Canada recommended Merck's painkiller Vioxx be allowed back on the market despite some cardiovascular risk, and also said Pfizer's Celebrex should remain on the market. The panel recommended Pfizer's other arthritis drug, Bextra, also a Cox-2 inhibitor, be kept off the market, and said ibuprofen pain relievers, currently sold OTC, should be subject to restrictions. Health Canada must now decide whether to accept the panel's recommendations.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID